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 2012 Published by IFPA and Elsevier Ltd.1. Trophoblast deportation/placental-maternal exchange
(pre-natal genetic diagnosis, pre-eclampsia or pregnancy-
related diseases)
Chairs: Hideaki Masuzaki and Chie-Pein Chen.
Speakers: Justine Fitzgerald, Olivia Holland, Kiyonori Miura,
Guiying Nie, Toshihiro Takizawa.
1.1. Outline
During pregnancy the placenta releases a number of different
factors into the maternal circulation; these factors include
trophoblast derived material, cell-free DNA/RNA, growth factors
and proteases. Altered levels of these different factors have been
associated with progression of pregnancy complications such as
pre-eclampsia. Indeed, circulating levels of several growth factors
have previously been shown to be altered prior to clinical presen-
tation of pre-eclampsia. Increasingly non-invasive means of clinical
diagnosis are being sought, and the same holds true for complica-
tions of pregnancy. This workshop sought to discuss some of the
novel circulating markers currently being examined for diagnosis/
prediction of complications of pregnancy.
1.2. Summary
Kiyonori Miura discussed identiﬁcation of pregnancy-associated
microRNAs (miRNAs) and their circulating levels in plasma from
normal pregnant women and women with pre-eclampsia. The
association between the circulating levels of pregnancy-associated
miRNA and pre-eclampsia was investigated. Eighty-two placenta-
predominantly expressed miRNAs were selected, of which 24 were
identiﬁed as pregnancy-associated miRNAs. The chromosome 19
miRNA cluster (C19MC) at 19q31.42 is speciﬁcally expressed in the
placenta (66.7%). As cell-free pregnancy-related miRNA markers,
has-miR-515-3p and has-miR-519b-3p were selected from 30 and 50
region of C19MC. The plasma concentration of C19MC-derived
miRNAs (has-miR-515-3p and has-miR-519b-3p) increased signiﬁ-
cantly in plasma fromwomenwith pre-eclampsia compared to that
from normal pregnancy. Thus, pregnancy-associated miRNAs may
be useful molecular markers for monitoring the presence of pre-
eclampsia.
Toshihiro Takizawa discussed dysregulation of placental
hydroxysteroid (17-beta) dehydrogenase 1 (HSD17B1) by miR-210
and miR-518c in pre-eclampsia, with plasma levels of HSD17B1 as
a novel marker for predicting late-onset pre-eclampsia. It was
identiﬁed that miR-210 and miR-518c were upregulated in human
pre-eclamptic placentas. These miRNAs were shown to target the
mRNA encoding HSD17B1, a placenta-speciﬁc steroidogenic
enzyme, expression of which is signiﬁcantly decreased in pre-
eclamptic placentas. Furthermore, it was found that plasma
HSD17B1 protein levels reﬂected its placental expression. A
prospective cohort study of plasma HSD17B1 revealed that
reducing plasma level of HSD17B1 precedes the onset of pre-
eclampsia and is a potential prognostic factor for pre-eclampsia.
Justine Fitzgerald discussed the thrombogeneic potential of
syncytiotrophoblast microparticles. Syncytiotrophoblast micro-
particles (STBMs) are involved in inﬂammation, immunomodula-
tion and endothelial dysfunction during pre-eclampsia. Recent dataindicate that STBMs also participate in coagulation, in particular
STBMs derived from pre-eclamptic placentae trigger thrombin
generation in a tissue factor-dependent manner. Data was pre-
sented conﬁrming the thrombogeneic potential of STBMs: overall
oxygen stabilized STBM release, as well as STBM-mediated
thrombin activation, ﬁbrin production and maximum platelet
aggregation. Insufﬁcient placental oxygen resulted in the opposite;
it elevated STBM-shedding, boosted thrombin activation and ﬁbrin
production, while accelerating the rate of platelet aggregation.
These emerging studies promise to open up a new research area
that sheds light on otherwise under-illuminated aspects of pre-
eclampsia.
Guiying Nie discussed HtrA3 as an early marker for pre-
eclampsia. HtrA3 (high temperature requirement A3), a serine
protease of the HtrA family, is important for placental development
and cancer progression. Recently, HtrA3 was identiﬁed as a poten-
tial biomarker for early detection of pre-eclampsia. This prompted
the generation of a panel of HtrA3-speciﬁc monoclonal antibodies
and development of an AlphaLISA assay suitable for large scale
screening of human serum. The assay detected signiﬁcantly higher
levels of serum HtrA3 at early gestation (13e14 weeks) in pregnant
women who subsequently developed pre-eclampsia than controls
in a small cohort. Large cohorts of appropriate serum samples will
be screened to determine the speciﬁcity and sensitivity of the assay
in predicting pre-eclampsia.
Olivia Holland discussed the use of whole genome ampliﬁcation
of syncytial nuclear aggregate DNA as a potential for minimally
invasive prenatal diagnostics. Syncytial nuclear aggregates (SNAs)
are a potential source of fetal/placental DNA for minimally-invasive
prenatal diagnostics. It was investigated whether DNA of sufﬁcient
quantity and quality for genetic testing was present in SNAs. Thirty-
six individual SNAs were collected in vitro and subjected to whole
genome ampliﬁcation. Single SNAs had a mean DNA yield of 135
(120) ng/mL. Twenty-ﬁve SNAs (69%) were considered to have
sufﬁcient DNA for downstream applications. These results show
that a high proportion of SNAs could be used for genetic testing
procedures; and suggest that SNAs have potential for use in
minimally-invasive prenatal diagnostics.
1.3. Conclusions
This workshop highlighted the potential of circulating
biomarkers, such as C19MC-derived miRNAs (has-miR-515-3p and
has-miR-519b-3p), HSD17B1 and HtrA3, as predictors of pre-
eclampsia. However, large scale cohorts are needed to validate
the speciﬁcities and sensitivities of these markers. In addition,
longitudinal studies are required to determine if these markers are
valid predictors of pre-eclampsia prior to clinical presentation of
the disease. Moreover, pre-eclampsia increased STBM-shedding
that activated thrombin and ﬁbrin production, and platelet aggre-
gation. Placenta-derived SNAs can be a potential source of fetal DNA
for prenatal diagnosis by the use of whole genome ampliﬁcation.
2. Gestational trophoblastic disease (GTD)
Chairs: Hidetaka Katabuchi and Kazuhiko Ino.
Speakers: Qi Chen, Eisuke Kaneki, Yusuke Kobayashi, Takashi
Ohba, Hirokazu Usui.
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Gestational trophoblastic disease (GTD) is a spectrum of
diseases with abnormal proliferation arising from placental
trophoblast which includes 4 main clinicopathological forms;
hydatidiform mole, invasive mole, choriocarcinoma and placental
site trophoblastic tumor (PSTT). Hydatidiform mole is an abnormal
pregnancy with trophoblast hyperplasia and hydropic chorionic
villi, and is divided pathologically and genetically into androgenetic
complete mole (CM) and triploid partial mole (PM). Approximately
10e20% of CM and <5% of PM progress to post-molar gestational
trophoblast neoplasia (GTN) requiring chemotherapy. Therefore,
correct differential diagnosis of CM and PM is important for the
management of these patients and early detection of GTN. The
mechanism by which hydatidiform mole progresses to invasive
mole or choriocarcinoma remains unclear. Multiple factors may be
involved including up- or down-regulation of speciﬁc oncogenes
and their proteins, some angiogenic factors and interaction with
host immune cells. Although the overall cure rate in treating GTN is
currently >90%, 〜10% of choriocarcinoma will develop chemo-
resistance and it remains to be fatal; thus, novel therapeutic
strategies are needed to achieve 100% survival.
This workshop included presentations on recent advances and
current research topics in the diagnosis of hydatidiform molar
pregnancy as well as in the treatment of post-molar GTN.2.2. Summary
Takashi Ohba discussed the clinical features of histologically
conﬁrmed early molar pregnancies. Early detection of pregnancy
has resulted in earlier diagnosis of hydatidiform mole. Early stage
hydatidiform moles are not hydropic but appear as thickened
intrauterine layers with an irregular surface. However, these
features are not pathognomonic because similar ﬁndings are also
observed in non-molar abortion. Evaluation of early hydatidiform
mole cannot predict impending post-molar trophoblast disease.
Follow-up of hCG levels, similar to the management of classical
mole, is also required to detect any subsequent development of
post-molar trophoblast disease.
Eisuke Kaneki discussed the incidence of post-molar gestational
trophoblast disease in androgenetic moles and the morphological
features associated with low risk, post-molar gestational tropho-
blast disease. The outcomes of 200 genetically diagnosed molar
pregnancy cases (178 cases of androgenetic mole, 13 cases of dis-
permic triploids and nine cases of biparental diploids) were
reviewed. Twenty-ﬁve cases (14%) of androgenetic moles devel-
oped post-molar GTD, none of the patients with dispermic triploids
developed post-molar GTD, none of the patients with androgenetic
moles who had hydropic villi less than 2 mm in their shortest
diameter developed post-molar GTD. For patients with dispermic
triploids the risk of postmolar GTD is extremely low. The risk of
post-molar GTD is also low in patients with androgenetic moles
with small hydropic villi.
Qi Chen discussed the placental expression of angiogenic
growth factors, VEGF and endoglin, in pregnancies with hydatidi-
form mole. Hydatidiform mole is an abnormal pregnancy with
over-proliferation of the placenta, which causes placental
dysfunction. Hydatidiform moles are also associated with devel-
opment of very early onset pre-eclampsia, which may be due to an
imbalance of angiogenic growth factor levels. Levels of VEGF and
endoglin in hydatidiform moles were studied, with levels of VEGF
but not endoglin being signiﬁcantly increased in hydatidiform
molar placentae in comparison to normal placentae. These data
suggest the increased levels of angiogenic factors VEGF inhydatidiform moles may link to the mechanism of developing very
early onset pre-eclampsia.
Yusuke Kobayashi discussed the establishment of a new
choriocarcinoma cell line, induced choriocarcinoma cell-1 (iC3-1),
which was generated from HTR8/SVneo retrovirally transduced
with activated HRAS. Interestingly, iC3-1 produces lethal tumors
consisting of syncytiotrophoblast and cytotrophoblast cells,
mimicking the clinical pathology. Microarray analysis between iC3-
1 and parental HTR8/SVneo revealed that iC3-1 expressed matrix
metalloproteinase (MMP) and EMT (epithelialemesenchymal
transition) related genes, as well as SOX3. Treatment with
shSOX3 attenuated the tumorigenic activity of iC3-1, suggesting
SOX3 overexpression might be critically involved in the tumori-
genesis of choriocarcinoma. Collectively, these data suggest iC3-1
may have the potential to become a powerful tool for investigation
of the choriocarcinoma tumorigenesis and pathogenesis.
Hirokazu Usui discussed the relationship between poly-
morphisms of folate metabolic enzyme genes and GTD. Metho-
trexate (MTX) is a key drug for treatment of trophoblastic
neoplasia. The target of MTX is the folate metabolic pathway. The
C677T polymorphism of methylenetetrahydrofolate reductase
(MTHFR) is a candidate gene for predictors of MTX treatment. The
C677T polymorphism of both peripheral blood cells and molar
tissues of low-risk gestational trophoblastic neoplasia (GTN) cases
were investigated. The molar CC genotype of MTHFR C677T corre-
lated with a favorable result after 5-days MTX therapy for low-risk
GTN.2.3. Conclusions
In this workshop, recent advances and current topics in the
diagnosis/management of hydatidiformmolar pregnancy as well as
in the treatment of post-molar gestational trophoblastic neoplasia
(GTN) were discussed. For the correct diagnosis of hydatidiform
moles, cytogenetical analysis and immunohistochemical studies
including angiogenic growth factor expression are important in
addition to conventional ultrasonographic or pathological analyses.
Furthermore, molecular analysis of mechanisms for malignant
transformation of GTN or genetic analysis of post-molar GTN may
contribute to development of novel therapeutic strategies, and also
to improvement of survival rates of GTN patients.3. Placental insufﬁciency and fetal growth restriction
Chairs: Akira Mori and Padma Murthi.
Speakers: Frederic Chantraine, Tiziana Cotechini, Akane Kondo,
Padma Murthi.3.1. Outline
Establishment and growth of the placental vasculature are key
determinants of fetal growth and development. Placental insufﬁ-
ciency due to inadequate remodeling of the spiral arteries is
a reﬂection of impaired blood ﬂow to the placenta. It is associated
with the maternal syndrome of pre-eclampsia and the fetal
syndrome of fetal growth restriction (FGR, also known as intra-
uterine growth restriction, IUGR). The precise mechanism of FGR in
most cases remains elusive, although placental insufﬁciency
appears to be a common feature. Placental examination may be
treated with less attention than examination of the fetus or the
pregnant uterus. The workshop focused on two themes: 1) imaging
placental insufﬁciency associated with FGR; 2) placental insufﬁ-
ciency associated with placental maldevelopment and function.
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Frédéric Chantraine discussed the use of magnetic resonance
imaging (MRI) for imaging placental insufﬁciency associated with
FGR. FGR is associated with an increased risk of perinatal morbidity
and mortality. Possible causes are chromosomal defects, congenital
malformations, fetal infections and “last but not least” placental
insufﬁciency. Ultrasound is the ﬁrst choice and standard imaging
method for fetal and placental evaluation in FGR. MRI has proven to
be of additional diagnostic value in the assessment of abnormal
placental invasion like placenta accreta. Furthermore, recent
scientiﬁc papers highlight the beneﬁt of “functional” MRI in the
assessment of placental insufﬁciency and FGR.
Akane Kondo discussed the use of ultrasound for imaging
placental insufﬁciency associated with FGR. It is still difﬁcult to
predict the incidence of severe FGR before it occurs. The stiffness of
the maternal abdominal aorta (AA) has been studied in normal
pregnant women and compromised pregnant women (increased
peripheral resistance). In the normal group, the Stiffness Index (SI)
was increased with the maternal age. In the compromised group,
aortic diameter and blood pressure were normal, but SI during the
second trimester was increased. The compromised women with
higher SI had a signiﬁcantly higher prevalence of FGR (P < 0.001).
This study shows that a progressive increase of the SI is associated
with severity of the disease.
Padma Murthi discussed expression of the progesterone
receptor (PR) in FGR. The deﬁnition of FGR is critical, true FGR being
deﬁned as a birth weight less than the 10th centile for gestation,
together with evidence of fetal health compromise evaluated by
Doppler ultrasound. The majority of FGR cases are due to unknown
cause, are termed idiopathic and are frequently associated with
placental insufﬁciency. The presented study was aimed to under-
stand the role of progesterone in feto-placental growth by exam-
ining expression patterns of PR. It was shown that PR is expressed
in the syncytiotrophoblast and chorionic vessels of the placenta,
and its expression is decreased in FGR suggesting that PR may
contribute to inadequate feto-placental blood ﬂow in idiopathic
FGR.
Tiziana Cotechini discussed whether there was a link between
abnormal maternal inﬂammation and development of FGR or pre-
eclampsia. Abnormal maternal inﬂammation is often associated
with FGR. Using a rat model of LPS-induced FGR, it has been
investigated whether abnormal maternal inﬂammation is causally
linked to altered utero-placental hemodynamics leading to
impaired fetal growth. Daily administration of low-dose LPS leads
to an increased spiral artery resistance index, impaired spiral artery
remodeling, elevated mean arteriole pressure, and FGR. These LPS-
induced alterations were prevented by a TNF-a inhibitor, thereby
establishing a critical role of TNF-a in the pathophysiology of
inﬂammation-induced FGR. These ﬁndings suggest that manage-
ment of inﬂammationmay be a potential strategy in the prevention
of FGR.3.3. Conclusions
The term placental insufﬁciency has long existed to indicate
a state of inadequate blood ﬂow through the placenta. The advent
of ultrasonography has facilitated the study of the placenta.
Moreover, MRI and echo-tracking method has proven to be of
additional diagnostic value in the assessment of the placenta
associated with FGR. Abnormal maternal inﬂammation and
decreased progesterone receptor expression are causally linked to
altered utero-placental as well as feto-placental hemodynamics
leading to FGR.4. Trophoblast over-invasion and accreta-related pathologies
Chairs: Nick Illsley and Abdullah Al-Khan.
Speakers: Judith Bulmer, Sally Collins, Tai-Ho Hung, Mushi
Matjila, Philipp Velicky.
4.1. Outline
Accreta-related pathologies and the trophoblast over-invasion
which underlies them are becoming a signiﬁcant area of clinical
concern as rising caesarean section rates increase the incidence of
these pathologies. The potentially disastrous clinical outcomes in
these cases are driving new clinical practices and new methods of
diagnosis. These necessitate an understanding of this problem not
only from the point of view of the clinician but also by the basic
scientists searching for markers of disease initiation, progression
and severity. Research into placenta accreta-related pathologies
and trophoblast over-invasion is relatively under-developed.
Nevertheless we have the advantage of being able to draw on
well-established ﬁelds of research such as mechanisms of tropho-
blast invasion and trophoblast under-invasion in pre-eclampsia to
help shape new studies in this ﬁeld. This workshop was designed
with several aims in mind: 1) To introduce placentologists to the
clinical problems and initiatives in this ﬁeld; 2) To draw together
and discuss possible mechanisms behind the accreta-related
pathologies; 3) To assist in linking the efforts of clinical and basic
scientists in the ﬁeld.
4.2. Summary
Tai-Ho Hung introduced the clinical practices and problems
facing clinicians dealing with accreta-related pathologies. Accreta-
related pathologies have increased in incidence at least 10-fold,
from 1 in 30,000 pregnancies in the 1950s to 1 in 2500 today. Much
of this increase is due to the rising incidence of caesarean delivery.
However many cases of placenta previa and accreta occur in the
absence of caesarean scar or any other manipulation of the uterus,
suggesting that placenta previa is at least as important as disrup-
tion of the endometrium/decidua. Management of placenta accreta
has changed remarkably with advances in diagnostic imaging, the
emergence of centers and specialized interdisciplinary teams for
patient management. The most obvious favorable change has been
anticipatory management. This requires ensuring that caesarean
delivery and hysterectomy, if needed, occurs in a controlled setting,
with advance preparations for hemorrhagic emergency and remote
from labor. Nonetheless questions remain as to the optimal tech-
niques for obtaining hemostasis and the timing of delivery in order
to maximize maturity of the fetus while minimizing risk to the
mother. Techniques reviewed here included Bakri balloon occlu-
sion, embolization, and hypogastric (aka internal iliac) artery
ligation.
Sally Collins discussed new studies in diagnostic ultrasound.
Maternal mortality and morbidity are reduced when women with
placenta accreta deliver in a tertiary care hospital with a multidis-
ciplinary care team. Current diagnosis rests on subjectively
assessing ultrasound and MRI images. The degree of severity and
therefore the team required at delivery depends on the ‘expert
opinion’. With a subjective test, and signiﬁcant consequences if
accreta is missed, there is always a risk of over diagnosis, which has
signiﬁcant maternal and neonatal implications. The development
of a novel 3-D power Doppler image analysis tool which provides
a quantitative assessment of the size and depth of invasion in cases
of placenta accreta was discussed.
Judith Bulmer discussed potential mechanisms of trophoblast
over-invasion. Extravillous trophoblast cells (EVT) are naturally
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matrix in vitro declines with increasing gestational age. Many
different growth factors and cytokines have been proposed to play
roles in regulating EVT invasion, with many of these found to
inhibit the process. A recent study of placenta accreta demon-
strated areas of accretawere often focal, with ‘normal’ invasion and
spiral artery remodeling occurring in the areas of non-accreta.
However, in the areas of accreta (with no decidua) trophoblast
giant cell numbers and degree of spiral artery transformation were
reduced compared to areas with decidua from the same patient.
This suggests a critical role for decidua in regulating trophoblast
invasion and terminal differentiation.
Philipp Velicky discussed the role of the Notch-dependent RBPJk
transcription factor in trophoblast invasion. The canonical Notch-
modulator and transcription factor Recombining Binding Protein-
Jk (RBPJk) and its co-activators, the Mastermind-like proteins
(MAML) 2 and MAML3, were shown to be present in ﬁrst-trimester
human villous and extravillous trophoblast (EVT) cells. MAML2
expression signiﬁcantly increased during trophoblast invasion.
Knock-down of RBPJk in SGHPL-5 trophoblast-like cells using siRNA
mediated gene silencing decreased their invasiveness whereas
RBPJk-dependent Notch reporter activity was elevated, suggesting
a repressive function of RBPJk in these cells. On the other hand,
outgrowth was increased in human ﬁrst-trimester placental
explants upon silencing RBPJk, indicating elevated proliferative
capacity. Taken together, these data suggest that activation of
canonical Notch signaling may represent a mechanism to restrain
trophoblast invasiveness.
Mushi Matjila discussed possible roles for Kiss in the patho-
physiology of placenta accreta. Kiss1 and kisspeptins have previ-
ously been reported as inhibitors of trophoblast cell invasion. In
healthy human pregnancies the expression of Kiss1 (mRNA and
protein), Kiss1R (mRNA and protein) and MMP9 (mRNA) were
greater in the placenta compared with placental bed and decidua
parietalis, while VEGF-A (mRNA and protein) and VEGFR2 (mRNA)
were highest in the placental bed. Based on these data several
hypotheses/scenarios that could explain the pathophysiology of
placenta accreta were posed. (1) There may be markedly decreased
Kiss1 transcript and protein expression by the placenta in accreta.
(2) In accreta there could be decreased Kiss1 Receptor (Kiss1R)
across the placenta, placental bed and decidua parietalis. (3) In
placenta accreta overexpression of matrix metalloproteinases
(MMPs), MMP9 in particular, by the placenta could explain over-
invasion. Interestingly an inverse relationship between placental
Kiss1 and MMP9 expression has been documented in pathological
pregnancies. (4) That there possibly exists a balance in angiogenesis
between the invading trophoblast and native maternal tissues.4.3. Conclusions
It was clear from the presentations and the discussions that fol-
lowed that the problem of accreta-related pathologies is attracting
a signiﬁcant amount of attention as a result of the caesarean-driven
increase in cases. As a result, new collaborative networks are being
set up in North America (Drs. Abdulla Al-Khan and Stacy Zamudio/
Hackensack University Medical Center) and Europe (Dr. Frédéric
Chantraine/University of Liege) to examine theproblem. Initially it is
likely that these networks will be concerned with exploring clinical
diagnostic and therapeutic modalities. Nevertheless, it is clear that
new factors regulating trophoblast invasion are now receiving
attention including kisspeptin and Notch signaling. There is now
good evidence to suggest that (abnormal) interaction between
extravillous trophoblast and decidual cells may be the key to
understandingdiseasemechanisms. This appears to be the directionbeing taken by basic science researchers investigating this
pathology.
5. Thrombosis and ﬁbrinolysis in the placenta and in still
birth
Chairs: Naohiro Kanayama, Mai He.
Speakers: Takayuki Iwaki, Mai He, Kotomi Nagahashi, Rashmi
Sood, Motoi Sugimura.
5.1. Outline
Placental circulation is critical for normal fetal growth and
maternal health. Thrombosis in the intervillous space can lead to
fetal growth restriction, fetal distress and still birth, while ﬁbrino-
lysis in the placenta can lead to abortion or placental abruption. The
balance between coagulation and ﬁbrinolytic factors in the
placenta is essential for maintaining pregnancy. This workshop
aimed to discuss current issues regarding thrombosis and ﬁbrino-
lysis in the placenta.
5.2. Summary
Kotomi Nagahashi discussed the role of the decidual ﬁbrin layer
in the maintenance of pregnancy. Plasminogen activator inhibitor
type 1 (PAI-1) is essential for maintenance of pregnancy and its
deﬁciency causes genital bleeding or placental hematoma. This
suggests that PAI-1 is closely related to formation of the ﬁbrinoid
layer (Nitabuch’s layer). PAI-1 protects the Nitabuch’s layer from
ﬁbrinolysis at the placental attachment site. An increase in ﬁbri-
nolysis could cause some disorders with genital bleeding in
pregnancy.
Takayuki Iwaki discussed the role of blood coagulation and
ﬁbrinolytic factors in the placenta. The potential importance of the
coagulation, anticoagulation, and ﬁbrinolytic systems in placenta
and maintaining pregnancy is based on the observation that ﬁbrin
deposits and ﬁbrin degradation products are resident in the feto-
maternal surfaces, and lack of maternal ﬁbrinogen results in
spontaneous abortion in early pregnancy in humans. Recently,
a complete SERPINE1 (PAI-1) deﬁciency was reported in humans. A
pregnancy without supplementation of PAI-1 via fresh frozen
plasma resulted in spontaneous abortion.
Rashmi Sood discussed the role of a maternal platelet response
to thrombin in regulating placental development and fetal growth
in a murine model of thrombophilia-associated pregnancy loss.
Interventions aimed at limiting placental thrombosis, such as
treatment with low molecular weight heparin (LMWH), are being
tested to prevent placental dysfunction and the related sequelae in
at-risk pregnancies. The risk-to-beneﬁt balance of antithrombotic
prophylaxis during pregnancy is a subject of intense ongoing
debate. Results from studies in murine models of placental failure
and fetal loss associated with defects in the thrombomodulin-
Protein C anticoagulation pathway were discussed.
Motoi Sugimura discussed heparin/heparin sulfate (HS)/
CD44v3-mediated signaling in the structural repair of a trophoblast
cell layer damaged by mechanical scratching. The effect of heparin/
HS/CD44v3-mediated processes during scratch wound closure was
evaluated in monolayer culture of immortalized human tropho-
blast cells derived from term placenta (TCL-1). The results suggest
that heparin/HS/CD44v3-mediated signaling enhances the repair of
the trophoblast cells layer damaged with mechanical scratching.
Mai He discussed a clinical case emphasizing the balance of
thrombosis and ﬁbrinolysis needed for successful pregnancy. The
patient had recurrent ﬁrst trimester pregnancy loss up to 8 times.
Most clinical workup results were negative, except for homozygous
A. Al-Khan et al. / Placenta 34, Supplement A, Trophoblast Research, Vol. 27 (2013) S11eS16S16MTHFR C677T mutation and positive family history. She was given
low molecular weight heparin (LMWH) since pregnancy #7, and
clinical decision was made to continue LMWH throughout the last
pregnancy (#9), which led to a live birth at 32 weeks. Placental
examination revealed massive perivillous ﬁbrin/ﬁbrinoid deposi-
tion and intraparenchymal hematoma, a reﬂection of dynamic and
heterogeneous balance between thrombosis and ﬁbrynolysis. The
speciﬁc histopathology in the placenta and prior POCs, its impact
on pregnancy, and potential mechanisms of heparin were
discussed.
5.3. Conclusions
The aim of this workshop was to discuss the importance of the
blood clotting and ﬁbrinolytic systems in the maintenance of
pregnancy. The role of ﬁbrin in decidua was discussed. It was
demonstrated that the lack of a ﬁbrinoid layer in decidua leads to
abortion or placental abruption. There have been a few previous
studies on the relationship between the ﬁbrinoid layer of deciduaand maintenance of pregnancy. Although many investigators have
focussed on blood coagulation and ﬁbrinolysis of the intervillous
space, the data presented here highlighted the importance of
decidual ﬁbrinoid in the maintenance of pregnancy. The other
presentations focussed on the effect of LMWH on thrombophila,
the treatment for hypercoagulative state of intervillous space and
decidual vessels. It was agreed that heparin/LMWH treatment is
effective for recurrent miscarriage resulting from a hyper-
coagulative status. It was emphasized that long term heparin/
LMWH treatment is required for successful maintenance of preg-
nancy in these cases. It is hoped that this workshop has highlighted
the importance of research on blood coagulation and ﬁbrinolysis in
the placenta as these processes are critical for prevention of preg-
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